A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies

Clinical trial NCT07135466 · RECRUITING

Trial details

NCT number: NCT07135466
Sponsor: Sheba Medical Center
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

B Cell Malignancies

Start date: 2026-02-01
Primary completion: 2027-04-01
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.